{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:18:38Z","timestamp":1790605118325,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Amiodarone is a class III antiarrhythmic drug that is commonly used in the clinic to treat ventricular arrhythmias and atrial fibrillation. We present a case report of the adverse effects of amiodarone and review its characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>A 73-year-old Asian female with a history of paroxysmal atrial fibrillation managed with amiodarone, well-controlled hypertension, and no substance abuse presented with gastrointestinal distress and dizziness, without chest pain or palpitations. Despite normal annual check-ups, she developed abnormal liver and thyroid function tests, and imaging revealed lung and liver changes suggestive of amiodarone toxicity. Discontinuation of amiodarone for sotalol led to symptom improvement and normalization of thyroid and liver functions, with imaging indicating recovery from interstitial fibrosis and reduced liver density.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Amiodarone, a widely used for treating ventricular and atrial arrhythmias, and with significant benefits in improving patient survival in cases of ventricular fibrillation. However, its long-term use is associated with serious adverse effects, including thyroid dysfunction, liver injury, and pulmonary toxicity, necessitating careful monitoring and management. Despite its efficacy, the need for research on early detection and management of amiodarone's side effects is crucial, highlighting the importance of regular monitoring and possibly adjusting therapy to mitigate these risks.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1401049","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T04:56:22Z","timestamp":1721192182000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Amiodarone-induced multi-organ toxicity"],"prefix":"10.3389","volume":"11","author":[{"given":"Jingrui","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B2","first-page":"2189","article-title":"Amiodarone: guidelines for use and monitoring","volume":"68","author":"Siddoway","year":"2003","journal-title":"Am Fam Physician"},{"key":"B3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMct065916","article-title":"Amiodarone for atrial fibrillation","volume":"356","author":"Zimetbaum","year":"2007","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0306-039X(75)90019-7","article-title":"Classification of antidysrhythmic drugs","volume":"1","author":"Vaughan Williams","year":"1975","journal-title":"Pharmacol Ther B"},{"key":"B5","doi-asserted-by":"publisher","first-page":"20R","DOI":"10.1016\/S0002-9149(99)00698-0","article-title":"Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent","volume":"84","author":"Kodama","year":"1999","journal-title":"Am J Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJM198702193160807","article-title":"Amiodarone","volume":"316","author":"Mason","year":"1987","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0735-1097(02)02705-5","article-title":"Amiodarone versus placebo and class IC drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis","volume":"41","author":"Chevalier","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/0002-8703(83)90006-6","article-title":"Amiodarone pharmacokinetics","volume":"106","author":"Holt","year":"1983","journal-title":"Am Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/clinchem\/35.9.1882","article-title":"Amiodarone and the thyroid","volume":"35","author":"Kennedy","year":"1989","journal-title":"Clin Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.tcm.2018.09.005","article-title":"Amiodarone and thyroid physiology, pathophysiology, diagnosis and management","volume":"29","author":"Trohman","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/europace\/euac217","article-title":"Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study","volume":"25","author":"Ali","year":"2023","journal-title":"Europace"},{"key":"B13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0002-9343(91)90187-3","article-title":"Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism","volume":"91","author":"Trip","year":"1991","journal-title":"Am J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nrendo.2009.225","article-title":"Effects of amiodarone therapy on thyroid function","volume":"6","author":"Cohen-Lehman","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2265.1987.tb00781.x","article-title":"Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases","volume":"26","author":"Martino","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.amjcard.2019.09.008","article-title":"Meta-analysis comparing the relative risk of adverse events for amiodarone versus placebo","volume":"124","author":"Ruzieh","year":"2019","journal-title":"Am J Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0953-6205(01)00127-3","article-title":"Pulmonary mass and multiple lung nodules mimicking a lung neoplasm as amiodarone-induced pulmonary toxicity","volume":"12","author":"Rodriguez-Garcia","year":"2001","journal-title":"Eur J Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1016\/j.jemermed.2010.07.024","article-title":"Amiodarone-induced acute respiratory distress syndrome masquerading as acute heart failure","volume":"43","author":"Kumar","year":"2012","journal-title":"J Emerg Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00392-010-0181-3","article-title":"Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?","volume":"99","author":"Schwaiblmair","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1007\/s001340000668","article-title":"Intravenous amiodarone in intensive care. Time for a reappraisal?","volume":"26","author":"Hughes","year":"2000","journal-title":"Intensive Care Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/01.CIR.82.1.51","article-title":"Clinical features of amiodarone-induced pulmonary toxicity","volume":"82","author":"Dusman","year":"1990","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijcard.2008.11.106","article-title":"Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity","volume":"140","author":"Nikaido","year":"2010","journal-title":"Int J Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0046-8177(87)80164-8","article-title":"Amiodarone lung: pathologic findings in clinically toxic patients","volume":"18","author":"Myers","year":"1987","journal-title":"Hum Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir Investig"},{"key":"B26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/eurheartj\/ehad726","article-title":"Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study","volume":"45","author":"Tsaban","year":"2024","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40256-020-00401-5","article-title":"Amiodarone: a comprehensive guide for clinicians","volume":"20","author":"Hamilton","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.1840090504","article-title":"Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients","volume":"9","author":"Lewis","year":"1989","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.tox.2004.02.017","article-title":"Flow-cytometric analysis on adverse effects of polysorbate 80 in rat thymocytes","volume":"199","author":"Hirama","year":"2004","journal-title":"Toxicology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/jcpt.12594","article-title":"Acute liver failure with amiodarone infusion: a case report and systematic review","volume":"43","author":"Jaiswal","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/ajhp\/60.17.1791","article-title":"Amiodarone\u2019s role in simvastatin-associated rhabdomyolysis","volume":"60","author":"de Denus","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.20703","article-title":"AASLD position paper: the management of acute liver failure","volume":"41","author":"Polson","year":"2005","journal-title":"Hepatology"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1401049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T04:56:25Z","timestamp":1721192185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1401049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2024.1401049"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1401049","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"article-number":"1401049"}}